Advanz Pharma and former private equity owners were fined £100m by markets watchdog
A pharmaceuticals firm that inflated thyroid drug prices by up to 6,000% over a decade paid out more than £400m to shareholders and directors during the same period.
London-based Advanz Pharma – and its former private equity owners HgCapital and Cinven – were fined a combined £100m by the Competition and Markets Authority (CMA) on Thursday.
Related: Pain aggravation: the human cost of medicine price hikes
Related: Price gouging fine for Advanz is a rare story that is becoming common | Phillip Inman
